Background and study aim: Metabolic associated fatty liver disease (MAFLD) is an increased serious clinical concern .Novel physical parameter, based on the properties of ultrasonic signals acquired by the Fibroscan®, is called the controlled attenuation parameter (CAP). This study aimed at assessing the role of CAP in disease staging in MAFLD patients.Patients and Methods: This is a comparative cross sectional study conducted on 84 patients diagnosed as having fatty liver by abdominal ultrasonography and, features of MAFLD according to international consensus guideline. Patients classified as MAFLD with chronic liver disease, HCV, HBV (Group 2) and MAFLD without other chronic liver disease (Group 1). Results: Most patients had marked hepatic steatosis. The diagnostic accuracy of CAP in disease staging in MAFLD patients was 88% at cut off value of >297 dB/m with sensitivity 88.5% and specifity 82.8%.The diagnostic accuracy of combined CAP and FLI(Fatty liver index) for diagnosis liver steatosis was 95% with sensitivity 96.2% and specifity 87.7%. Conclusion: CAP may be used as a promising noninvasive tool for assessment and quantifying of steatosis in MAFLD patients. Combination of both noninvasive imaging technique (CAP) and laboratory score (FLI) may improve the diagnostic accuracy in assessing steatosis in MAFLD patients .
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.